MedTrace Logo

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00749788 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2013-02-04

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of JTT-302 on the increase of High Density Lipoprotein-Cholesterol (HDL-C) levels when administered daily for four weeks in subjects with low HDL-C levels.

Conditions

Interventions

DRUG

JTT-302

JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal

DRUG

JTT-302

JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal

DRUG

Placebo

Matching placebo tablets, oral, 30 minutes after the start of the morning meal

Sponsors & Collaborators

  • Akros Pharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00749788 on ClinicalTrials.gov